Department of Anesthesiology and Resuscitology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Department of Anesthesiology and Resuscitology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
J Cardiothorac Vasc Anesth. 2024 Dec;38(12):3118-3126. doi: 10.1053/j.jvca.2024.08.038. Epub 2024 Sep 5.
To compare the incidence of hypotension between remimazolam and sevoflurane under general anesthesia for cardiac catheterization in patients with congenital heart disease.
Retrospective observational study.
A single university hospital with 300 pediatric cardiac catheterizations by general anesthesia performed annually.
Patients younger than 15 years who underwent cardiac catheterization under general anesthesia between March 1, 2021, and December 31, 2022. Exclusion criteria were general anesthesia maintained with other than remimazolam or sevoflurane, receipt of remifentanil, American Society of Anesthesiologists score 4 or 5, emergency procedures, and no direct arterial pressure measurement.
General anesthesia was maintained with remimazolam or sevoflurane.
A total of 309 patients were analyzed, including 28 in the remimazolam group and 281 in the sevoflurane group. Propensity score matching adjusted for confounding factors resulted in 28 patients in each arm, with no apparent differences in background factors. Hypotension was defined as a time-averaged area > 1, in which systolic arterial pressure fell below 80% of the baseline from the start of anesthesia to the end of procedure. The significance level was set at P < .05. The incidence of hypotension was 39.3% in the remimazolam arm and 46.4% in the sevoflurane arm, with no significant difference (P = .79), although the ratio of the median systolic arterial pressure to the baseline value was significantly higher in the remimazolam arm (91.4 ± 15.2% vs 83.2 ± 11.4% in the sevoflurane arm; P = .03).
Remimazolam was not associated with a lower incidence of hypotension compared to sevoflurane during pediatric cardiac catheterization for congenital heart disease while maintaining significantly higher blood pressure overall.
比较先天性心脏病患者全身麻醉下心导管检查时瑞马唑仑与七氟醚低血压的发生率。
回顾性观察性研究。
一家每年有 300 例全身麻醉下心导管检查的单一大学医院。
2021 年 3 月 1 日至 2022 年 12 月 31 日期间全身麻醉下心导管检查的年龄小于 15 岁的患者。排除标准为非瑞马唑仑或七氟醚维持的全身麻醉、接受瑞芬太尼、美国麻醉医师协会评分 4 或 5、急症手术和无直接动脉压测量。
瑞马唑仑或七氟醚维持全身麻醉。
共分析了 309 例患者,其中瑞马唑仑组 28 例,七氟醚组 281 例。倾向评分匹配调整混杂因素后,每组各有 28 例患者,背景因素无明显差异。低血压定义为时间平均面积 > 1,即从麻醉开始到手术结束时收缩压下降至基础值的 80%以下。显著性水平设为 P <.05。瑞马唑仑组低血压发生率为 39.3%,七氟醚组为 46.4%,差异无统计学意义(P =.79),但瑞马唑仑组收缩压与基础值的比值明显较高(91.4 ± 15.2%比 73.2 ± 11.4%;P =.03)。
与七氟醚相比,瑞马唑仑在先天性心脏病儿童心导管检查中并不降低低血压的发生率,但总体上血压维持更高。